Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome

Summary

This is an open label study of mepolizumab 750 mg intravenous in those subjects who participated in study 100185 to evaluate the long term safety and efficacy of mepolizumab in subjects with hypereosinophilic syndrome. The study will also evaluate the optimal dosing frequency for clinical use, the effects on corticosteroid reduction, and decrease of signs and symptoms of Hypereosinophilic Syndrome.

Timeline

Start

2004-09-30

Primary completion

2010-09-29

Completion

2010-09-29

Drugs

Indications